PGAP2

Across TCGA pan-cancer cohorts, PGAP2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PGAP2 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PGAP2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PGAP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, BLCA, and UCEC are the cancer types where PGAP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.140	0.781	<.001	9	view →
BLCA	DFS	Median	All	0.174	0.625	.023	6	view →
UCEC	DFS	Median	All	1.000	0.625	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PGAP2–COAD (DFS)

Open the COAD breakdown →